Among them, amyloid and tau imaging ligands were used to assess directly Alzheimer’s’s disease (AD) lesion burden in the human brain, whereas MRI volumetry and FDG-PET metabolic data in AD signature cortical areas are thought to explore downstream cell events leading to neuronal loss. Here, MAPT is linked to Alzheimer disease.